NCT00074867View on ClinicalTrials.gov

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

September 30, 2004

Conditions
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
Interventions
DRUG

CP-547,632

Trial Locations (9)

10016

Pfizer Investigational Site, New York

21237

Pfizer Investigational Site, Baltimore

90095

Pfizer Investigational Site, Los Angeles

90404

Pfizer Investigational Site, Santa Monica

02114

Pfizer Investigational Site, Boston

02115

Pfizer Investigational Site, Boston

02215

Pfizer Investigational Site, Boston

L8V 5C2

Pfizer Investigational Site, Hamilton

G1R 2J6

Pfizer Investigational Site, Québec

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY